Literature DB >> 23771323

Barrett's esophagus in the patients with familial adenomatous polyposis.

Zoran Gatalica1, Mingkui Chen, Carrie Snyder, Sumeet Mittal, Henry T Lynch.   

Abstract

Familial adenomatous polyposis (FAP) is caused by germ line mutations in the APC gene. Barrett's esophagus (BE) and Barrett's adenocarcinoma are intestinal type lesions of the esophagus characterized by an early loss of heterozygosity at the APC locus. We hypothesized that patients with FAP are at risk for the early development of BE due to the inherited mutations in the APC gene (haploinsufficiency). Upper gastrointestinal (UGI) tract biopsies from 36 patients with FAP were reviewed to determine the incidence and characteristics of BE in these patients. Twenty-four patients were confirmed carriers of a deleterious germline APC mutation. The other 12 patients were from FAP families with known APC gene mutations and had clinical manifestations of FAP. The control group consisted of patients who did not have a personal or family history of FAP undergoing UGI endoscopic examination in our institution over a 30 month period of time. The difference in expression of Wnt pathway proteins (APC, β-catenin, E-cadherin and cyclin D1) in BE between BE(+)/FAP(+), BE(-)/FAP(+) and age-matched BE(+)/FAP(-) groups was studied using immunohistochemistry. BE was found in 6 of 36 (6/36 or 16%) patients with FAP and in 266 of 1662 patients (16%) in the control group of symptomatic patients. The average age at the first diagnosis of BE in FAP patients was 37.8 versus 57.5 years in the control group (sporadic BE). When compared to age matched BE(+)/FAP- group (7/334), patients with FAP had a significantly (p = 0.005843, odds ratio 9.2; Fisher exact test) higher incidence of BE. Both classic FAP and attenuated FAP phenotypes were associated with BE .Two types of germ line mutations in APC gene were identified in BE(+)/FAP(+) patients: Five patients had 2-base deletion in exon 4 (426delAT) and one patient had 4-base deletion in exon 15 (3202del4). No difference in Wnt signaling pathway proteins expression was detected between BE(+)/FAP(+) and the age matched group of patients with sporadic BE (BE(+)/FAP(-)). Patients with FAP appear to have increased risk for the development of BE, which on average develops some 20 years earlier than in patients without FAP. This association needs to be taken in account when caring for the patients with FAP.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23771323     DOI: 10.1007/s10689-013-9638-7

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  23 in total

1.  Cdx-2 expression in squamous and metaplastic columnar epithelia of the esophagus.

Authors:  D Vallböhmer; S R DeMeester; J H Peters; D S Oh; H Kuramochi; D Shimizu; J A Hagen; K D Danenberg; P V Danenberg; T R DeMeester; P T Chandrasoma
Journal:  Dis Esophagus       Date:  2006       Impact factor: 3.429

2.  Barrett esophagus with progression to adenocarcinoma in multiple family members with attenuated familial polyposis.

Authors:  Mayuri Gupta; Deepti Dhavaleshwar; Gupta Vipin; Radheshyam Agrawal
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-05

Review 3.  Barrett's esophagus.

Authors:  S J Spechler; R K Goyal
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

Review 4.  The genetics of FAP and FAP-like syndromes.

Authors:  Lara Lipton; Ian Tomlinson
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

Review 5.  Targeting the Wnt signaling pathway to treat Barrett's esophagus.

Authors:  Geneviève Clément; David M Jablons; Jean Benhattar
Journal:  Expert Opin Ther Targets       Date:  2007-03       Impact factor: 6.902

6.  Variation in age at cancer diagnosis in familial versus nonfamilial Barrett's esophagus.

Authors:  Amitabh Chak; Yanwen Chen; Jaime Vengoechea; Marcia I Canto; Robert Elston; Gary W Falk; William M Grady; Kishore Guda; Margaret Kinnard; Sanford Markowitz; Sumeet Mittal; Ganapathy Prasad; Nicholas Shaheen; Joseph E Willis; Jill S Barnholtz-Sloan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-12-16       Impact factor: 4.254

Review 7.  High-grade dysplasia in sporadic fundic gland polyps: clinically relevant or not?

Authors:  Manfred Stolte; Michael Vieth; Matthias P Ebert
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-11       Impact factor: 2.566

Review 8.  Pathology of the hereditary colorectal carcinoma.

Authors:  Zoran Gatalica; Emina Torlakovic
Journal:  Fam Cancer       Date:  2007-06-13       Impact factor: 2.375

Review 9.  Consortium approach to identifying genes for Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Heather M Ochs-Balcom; Gary Falk; William M Grady; Margaret Kinnard; Joseph Willis; Robert Elston; Charis Eng; Amitabh Chak
Journal:  Transl Res       Date:  2007-05-25       Impact factor: 7.012

10.  Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma.

Authors:  Z Zhuang; A O Vortmeyer; E J Mark; R Odze; M R Emmert-Buck; M J Merino; H Moon; L A Liotta; P H Duray
Journal:  Cancer Res       Date:  1996-05-01       Impact factor: 12.701

View more
  3 in total

1.  Prevalence and risk factors of barrett's esophagus in lynch syndrome.

Authors:  Natalie Farha; Ruishen Lyu; David Liska; Amit Bhatt; Carole Macaron; Carol A Burke
Journal:  Fam Cancer       Date:  2022-06-02       Impact factor: 2.375

Review 2.  Hereditary Factors in Esophageal Adenocarcinoma.

Authors:  Anna M J van Nistelrooij; Winand N M Dinjens; Anja Wagner; Manon C W Spaander; J Jan B van Lanschot; Bas P L Wijnhoven
Journal:  Gastrointest Tumors       Date:  2014-05-09

3.  Increased prevalence of Barrett's esophagus in patients with MUTYH-associated polyposis (MAP).

Authors:  Ceranza G Daans; Zeinab Ghorbanoghli; Mary E Velthuizen; Hans F A Vasen; George J A Offerhaus; Miangela M Lacle; Peter D Siersema; Margreet G E M Ausems; Jurjen J Boonstra
Journal:  Fam Cancer       Date:  2020-04       Impact factor: 2.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.